ARCHIVES

Revlimid Plus Steroid Effective In Clinical Trial

This article is from The Cancer Letter archive.

Vol. 30 No. 11 | November 30, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Senate Subcommittee Recommends $1 .52 Billion

September 25, 1987

Orlando Health President Mark Rohl We Opted For A Florida-Centric Strategy

January 10, 2014

Most of NCI’s Increase For Breast Cancer to Fund Grants: Broder

May 21, 1993

NCI Plans Briefing Oct. 8 In St. Louis for SPORE Applicants

August 23, 1991

Partial Responses To Zactima In Thyroid Cancer Trial

January 27, 2006

Chart Show 1980 Budget Breakown By Mechanisms, Research Programs, Compare Them With Previous Years

June 9, 1978